Skip to main content

Table 4 The cumulative incidences and multivariate subdistribution proportional hazards analysis on CSD

From: Is lobectomy superior to sub-lobectomy in non-small cell lung cancer with pleural invasion? A population-based competing risk analysis

Characteristics

Cause-specific death (%)

Subdistribution proportional hazards model

1-year CIF

3-year CIF

5-year CIF

Gray’s test

P value

HR

95% CI

P value

Year at diagnosis

   

1.31

0.251

   

 2010–2012

0.13

0.33

0.41

     

 2013–2015

0.12

0.3

0.41

     

Age

   

83.16

0.011

1.02

0.98–1.03

< 0.001

Gender

   

7.94

0.005

   

 Female

0.11

0.28

0.37

  

Reference

  

 Male

0.14

0.34

0.43

  

1.18

0.85–1.36

0.031

Race

   

1.2

0.273

   

 White

0.13

0.32

0.41

     

 Non-White

0.12

0.3

0.39

     

Marital status

   

0.17

0.681

   

 Married

0.12

0.31

0.41

     

 Unmarried

0.13

0.31

0.39

     

Grade

   

35.71

< 0.001

   

 I

0.09

0.23

0.28

  

Reference

  

 II

0.09

0.27

0.37

  

1.37

0.72–1.91

0.062

 III

0.17

0.37

0.46

  

1.64

0.61–2.3

0.004

 IV

0.27

0.58

0.63

  

2.63

0.38–4.9

0.002

T stage

   

108.79

< 0.001

   

 T2

0.08

0.23

0.32

  

Reference

  

 T3

0.19

0.44

0.53

  

1.31

0.77–1.63

0.021

 T4

0.28

0.5

0.64

  

1.29

0.78–1.80

0.143

N stage

   

107.91

< 0.001

   

 N0

0.1

0.26

0.33

  

Reference

  

 N1

0.15

0.37

0.51

  

1.8

0.55–2.23

< 0.001

 N2

0.21

0.49

0.62

  

2.48

0.40–3.03

< 0.001

 N3

0.2

0.6

NA

  

2.03

0.50–5.19

0.141

Metastasis

   

78.48

< 0.001

   

 M0

0.11

0.29

0.38

  

Reference

  

 M1

0.38

0.63

0.7

  

2.62

0.38–3.57

< 0.001

Pathology

   

10.46

0.005

   

 Adenocarcinoma

0.1

0.28

0.39

  

Reference

  

 Others

0.33

0.49

0.51

  

1.53

0.65–2.48

0.081

 Squamous cell carcinoma

0.17

0.38

0.44

  

1.02

0.98–1.22

0.872

Pleural invasion

   

54.91

< 0.001

   

 PL-1

0.1

0.27

0.34

  

Reference

  

 PL-2

0.13

0.31

0.43

  

1.1

0.91–1.30

0.245

 PL-3

0.21

0.48

0.57

  

1.57

0.64–2.01

< 0.001

Primary site

   

7.16

0.028

   

 Lower lobe

0.13

0.35

0.45

  

Reference

  

 Others

0.13

0.3

0.39

  

1.06

0.94–1.42

0.68

 Upper lobe

0.12

0.29

0.38

  

0.87

0.65–2.48

0.108

Laterality:

   

6.72

0.011

   

 Left

0.14

0.34

0.43

  

Reference

  

 Right

0.12

0.29

0.39

  

0.87

0.73–1.15

0.061

Tumor size

   

547.18

< 0.001

   

Radiation

   

44.65

< 0.001

   

 None

0.11

0.28

0.37

  

Reference

  

 Radiotherapy

0.19

0.45

0.57

  

1.28

0.78–1.56

0.013

Chemotherapy

   

15.67

< 0.001

   

 None

0.12

0.28

0.37

  

Reference

  

 Chemotherapy

0.14

0.37

0.46

  

0.77

0.65–1.29

0.009

Surgery

   

4.45

0.036

   

 Lobectomy

0.12

0.3

0.39

  

Reference

  

 Sub-lobectomy

0.16

0.38

0.45

  

1.24

0.81–1.51

0.035

  1. HR Hazard ratio
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us